Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2014 1
2015 1
2016 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).
Landewé RB, Gensler LS, Poddubnyy D, Rahman P, Hojnik M, Li X, Liu Leage S, Adams D, Carlier H, Van den Bosch F; COAST-Y study group. Landewé RB, et al. Ann Rheum Dis. 2021 Aug;80(8):1022-1030. doi: 10.1136/annrheumdis-2020-219717. Epub 2021 May 6. Ann Rheum Dis. 2021. PMID: 33958326 Free PMC article. Clinical Trial.
Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study.
Alten R, Nüßlein H, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, Elbez Y, Le Bars M. Alten R, et al. RMD Open. 2016 Feb 15;2(1):e000228. doi: 10.1136/rmdopen-2015-000228. eCollection 2016. RMD Open. 2016. PMID: 26925253 Free PMC article.
Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.
Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, Le Bars M. Nüßlein HG, et al. BMC Musculoskelet Disord. 2015 Jul 30;16:176. doi: 10.1186/s12891-015-0636-9. BMC Musculoskelet Disord. 2015. PMID: 26228643 Free PMC article.
Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.
Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Peichl P, Pavelka K, Chartier M, Poncet C, Rauch C, Le Bars M. Nüßlein HG, et al. Clin Exp Rheumatol. 2016 May-Jun;34(3):489-99. Epub 2016 Mar 10. Clin Exp Rheumatol. 2016. PMID: 26966919
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.
Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Rainer F, Pavelka K, Chartier M, Poncet C, Rauch C, Bars ML. Nüßlein HG, et al. BMC Musculoskelet Disord. 2014 Jan 11;15:14. doi: 10.1186/1471-2474-15-14. BMC Musculoskelet Disord. 2014. PMID: 24410774 Free PMC article.
The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement.
Gossec L, Paternotte S, Maillefert JF, Combescure C, Conaghan PG, Davis AM, Gunther KP, Hawker G, Hochberg M, Katz JN, Kloppenburg M, Lim K, Lohmander LS, Mahomed NN, March L, Pavelka K, Punzi L, Roos EM, Sanchez-Riera L, Singh JA, Suarez-Almazor ME, Dougados M; OARSI-OMERACT Task Force "total articular replacement as outcome measure in OA". Gossec L, et al. Osteoarthritis Cartilage. 2011 Feb;19(2):147-54. doi: 10.1016/j.joca.2010.10.025. Epub 2010 Oct 31. Osteoarthritis Cartilage. 2011. PMID: 21044689 Free PMC article.